Quest Diagnostics (DGX) Projected to Post Earnings on Thursday

Quest Diagnostics (NYSE:DGX) is projected to release its earnings data before the market opens on Thursday, January 30th. Analysts expect Quest Diagnostics to post earnings of $2.19 per share and revenue of $2,577,440.00 billion for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Quest Diagnostics Trading Up 3.0 %

NYSE DGX opened at $159.94 on Tuesday. The company has a market capitalization of $17.85 billion, a PE ratio of 21.50, a P/E/G ratio of 2.36 and a beta of 0.90. The company has a fifty day moving average of $155.66 and a 200 day moving average of $153.21. Quest Diagnostics has a 1 year low of $123.04 and a 1 year high of $165.32. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.25 and a quick ratio of 1.17.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 29th. Investors of record on Tuesday, January 14th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $3.00 dividend on an annualized basis and a yield of 1.88%. Quest Diagnostics’s dividend payout ratio is presently 40.32%.

Insider Activity at Quest Diagnostics

In related news, CAO Michael J. Deppe sold 18,755 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the completion of the sale, the chief accounting officer now owns 34,941 shares of the company’s stock, valued at approximately $5,382,661.05. This represents a 34.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.79% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on DGX. Baird R W upgraded shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 23rd. StockNews.com cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th. Piper Sandler lifted their price objective on shares of Quest Diagnostics from $150.00 to $165.00 and gave the company a “neutral” rating in a report on Monday, October 28th. Mizuho lifted their price objective on shares of Quest Diagnostics from $160.00 to $174.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Finally, Leerink Partnrs raised shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 6th. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $172.15.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.